Last reviewed 2026-05-15 · How we verify

ARRY-502, CRTh2 antagonist; oral

Pfizer · Phase 2 active Small molecule

ARRY-502, CRTh2 antagonist; oral is a CRTh2 antagonist Small molecule drug developed by Pfizer. It is currently in Phase 2 development for Allergic rhinitis.

Blocks CRTh2 receptor to reduce inflammation.

Blocks CRTh2 receptor to reduce inflammation. Used for Allergic rhinitis.

At a glance

Generic name	ARRY-502, CRTh2 antagonist; oral
Sponsor	Pfizer
Drug class	CRTh2 antagonist
Target	CRTh2
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 2

Mechanism of action

ARRY-502 works by selectively antagonizing the CRTh2 receptor, a key player in the inflammatory response. This action helps to reduce inflammation and alleviate symptoms associated with allergic diseases. By targeting CRTh2, ARRY-502 aims to provide a novel therapeutic approach for treating conditions characterized by excessive inflammation.

Approved indications

Allergic rhinitis

Common side effects

Headache

Key clinical trials

A Study of ARRY-502 in Patients With Persistent Asthma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ARRY-502, CRTh2 antagonist; oral CI brief — competitive landscape report
ARRY-502, CRTh2 antagonist; oral updates RSS · CI watch RSS
Pfizer portfolio CI

Frequently asked questions about ARRY-502, CRTh2 antagonist; oral

What is ARRY-502, CRTh2 antagonist; oral?

ARRY-502, CRTh2 antagonist; oral is a CRTh2 antagonist drug developed by Pfizer, indicated for Allergic rhinitis.

How does ARRY-502, CRTh2 antagonist; oral work?

Blocks CRTh2 receptor to reduce inflammation.

What is ARRY-502, CRTh2 antagonist; oral used for?

ARRY-502, CRTh2 antagonist; oral is indicated for Allergic rhinitis.

Who makes ARRY-502, CRTh2 antagonist; oral?

ARRY-502, CRTh2 antagonist; oral is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What drug class is ARRY-502, CRTh2 antagonist; oral in?

ARRY-502, CRTh2 antagonist; oral belongs to the CRTh2 antagonist class. See all CRTh2 antagonist drugs at /class/crth2-antagonist.

What development phase is ARRY-502, CRTh2 antagonist; oral in?

ARRY-502, CRTh2 antagonist; oral is in Phase 2.

What are the side effects of ARRY-502, CRTh2 antagonist; oral?

Common side effects of ARRY-502, CRTh2 antagonist; oral include Headache.

What does ARRY-502, CRTh2 antagonist; oral target?

ARRY-502, CRTh2 antagonist; oral targets CRTh2 and is a CRTh2 antagonist.

Drug class: All CRTh2 antagonist drugs
Target: All drugs targeting CRTh2
Manufacturer: Pfizer — full pipeline
Therapeutic area: All drugs in Immunology
Indication: Drugs for Allergic rhinitis
Compare: ARRY-502, CRTh2 antagonist; oral vs similar drugs
Pricing: ARRY-502, CRTh2 antagonist; oral cost, discount & access